Cuba will show results of lung cancer vaccine
The final results of the efficacy confirmation study of the Cuban vaccine CIMAvax-EGF in advanced lung cancer will be presented at the 5th International Workshop on the subject next Tuesday and Wednesday in Havana.
Considered a novel approach capable of generating antibodies on the patient against epidermal growth factor (EGF), CIMAvax-EGF is the first therapeutic vaccine for lung cancer registered.
The antibodies generated by this against EGF inhibit EGF activation and stop the proliferation of tumor cells. Consequently the progression of the disease is controlled; survival increases and significantly improves quality of life in treated patients.
Recently, CIM and the Roswell Park Institute against Cancer, in New York, signed an agreement to export to the United States this therapeutic vaccine against lung cancer, so clinical trials will soon begin.